BOR-I/S1/P2-001/L3/M1-05

Mfg.

Lot.

Exp.

MYELOMIB

Bortezomib

3.5mg

Lyophilized Powder for Solution for Injection
For Intravenous Or Subcutaneous Use Only

1 Vial (Single Dose)

Each vial contains 3.5 mg of Bortezomib

KEEP MEDICINE OUT OF REACH OF CHILDREN
JAUHI UBAT DARIPADA KANAK-KANAK

Please refer to the package insert for further information.

MAL XXXXXXXXXX

CAUTION: CYTOTOXIC AGENT

Controlled Medicine

MYELOMIB

Bortezomib

3.5mg

Lyophilized Powder for Solution for Injection
For Intravenous Or Subcutaneous Use Only

Reconstitution Information

SUBCUTANEOUS INJECTION ONLY	INTRAVENOUS INJECTION ONLY
Add 1.4 mL 0.9% Sodium Chloride	Add 3.5 mL 0.9% Sodium Chloride
To make 2.5 mg per mL final concentration	To make 1 mg per mL final concentration

Store below 30°C. Keep the vial in the outer carton in order to protect from light.

Reconstituted solution: Use immediately after preparation. If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. However, the reconstituted solution is stable for 8 hours at 25°C stored in the original vial and/or a syringe, with a total storage time for the reconstituted medicine not exceeding 8 hours prior to administration.

Discard unused portion.

Product Registration Holder:
Novugen Oncology Sdn. Bhd.
No. 3, Jalan Jururancang U1/21,
Hicom Glenmarie Industrial Park,
40150 Shah Alam, Selangor, Malaysia.

Manufactured by:
Jiangsu Hansoh Pharmaceutical Group Co., Ltd., No. 5, Dongjin Road, Economic and Technical Development Zone, Lianyungang, Jiangsu 222069, China.